The following is excerpted from Dr. Richard Louis Miller’s excellent new book,  Psychedelic Medicine. MDMA: Heart Medicine   Substance: MDMA (3,4- methylenedioxy-methamphetamine), aka Molly, Ecstasy, “X,” “E”, “XTC”, ADAM Schedule: I (No recognized medical use and high potential for abuse) Rick Doblin, Ph.D.: Drawing a Map from “X” to Rx March 5, 2013 (with excerpts from August 18, 2015) Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in public policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. RLM: Now it’s over 25 years from when you started MAPS. Tell us about the research that MAPS is sponsoring in these various psychedelic medicines. RD: The good news is that there is now more psychedelic research taking place around the world than at any time in the last 40 years. We’re basically combining science, politics, and psychedelics. . . . Our resources are limited and we want to do work that will have the biggest appeal to the American public.   Two Phases Down, One More to Approval RD: We started from what are called Phase I studies—working in a healthy population to evaluate what the drug does—to get a sense of … Continue reading From “X” to Rx: Discussing MDMA with Rick Doblin An Excerpt from “Psychedelic Medicine” by Dr. Richard Louis Miller